The Experts below are selected from a list of 1383 Experts worldwide ranked by ideXlab platform
Chui Ming Gemmy Cheung - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of a novel personalised aflibercept monotherapy regimen based on Polypoidal lesion closure in participants with Polypoidal Choroidal Vasculopathy
British Journal of Ophthalmology, 2021Co-Authors: Kelvin Yi Chong Teo, Tien Yin Wong, Ranjana Mathur, Anna C S Tan, Ian Yeo, Choi Mun Chan, Janice Marie Jordanyu, Usha Chakravarthy, Chui Ming Gemmy CheungAbstract:PURPOSE To compare the efficacy of aflibercept using a personalised versus fixed regimen in treatment-naive participants with Polypoidal Choroidal Vasculopathy (PCV). DESIGN A 52-week, randomised, open-label, non-inferiority, single-centre study that included participants with symptomatic PCV. Participants were randomised (3:1 ratio) to receive either personalised (n=40) or fixed 8-weekly treatment regimen (n=13). The personalised regimen allowed for either early treat and extend (TE difference 0.16, 95% CI -2.8 to 2.4, p=0.79). There was greater reduction in mean CSFT (SD) in the personalised versus fixed group (-248.8 (169.9) vs -164.8 (148.9) µm, p=0.03). Closure of PL occurred in 21 (55.2%) and 5 (41.6%) of study eyes in personalised and fixed groups, respectively at week 52 (p=0.41). CONCLUSIONS Personalised regimen achieved non-inferior BCVA gain and numerically higher PL closure compared with fixed regimen. TRIAL REGISTRATION NUMBER NCT03117634.
-
efficacy and safety of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy two year results of the aflibercept in Polypoidal Choroidal Vasculopathy study
American Journal of Ophthalmology, 2019Co-Authors: Tien Yin Wong, Chui Ming Gemmy Cheung, Shihjen Chen, Won Ki Lee, Yuichiro Ogura, Tomohiro Iida, Sergio Leal, Paul Mitchell, Zhongqi Zhang, Tatsuro IshibashiAbstract:Purpose We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with Polypoidal Choroidal Vasculopathy (PCV). Design This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers. Methods In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73–24 Early Treatment Diabetic Retinopathy Study letters (20/40–20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated. Results Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained (+10.7 vs +9.1, P = .48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed. Conclusion IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit.
-
Choroidal thickness changes in age related macular degeneration and Polypoidal Choroidal Vasculopathy a 12 month prospective study
American Journal of Ophthalmology, 2016Co-Authors: Daniel Shu Wei Ting, Tien Yin Wong, Ranjana Mathur, Choi Mun Chan, Wei Yan Ng, Si Rui Ng, Chui Ming Gemmy CheungAbstract:Purpose To describe 12-month changes in Choroidal thickness after anti–vascular endothelial growth factor (anti-VEGF) therapy for typical age-related macular degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV). Design Prospective, consecutive, noninterventional, longitudinal case series. Methods This study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month period. We used spectral-domain optical coherence tomography with enhanced depth imaging mode to measure Choroidal thickness. Results Of the 163 patients, 77 had typical AMD and 86 had PCV. Patients with PCV were younger (67.6 vs 72.5 years, P P = .02) than patients with typical AMD. Baseline subfoveal Choroidal thickness was not significantly different between PCV and typical AMD eyes, and was thicker in the study eye compared to fellow eye in the typical AMD group (223.1 vs 208.8 μm, P P P P = .04) and smoking (OR: 7.6, P = .03) at baseline, but not with age, refractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy, or baseline Choroidal thickness. Conclusions A significant reduction in subfoveal Choroidal thickness was noted after anti-VEGF therapy in typical AMD and PCV. Choroidal thickness changes were similar despite differences in number of anti-VEGF treatment.
-
the natural history of Polypoidal Choroidal Vasculopathy a multi center series of untreated asian patients
Graefes Archive for Clinical and Experimental Ophthalmology, 2015Co-Authors: Chui Ming Gemmy Cheung, Elizabeth Yang, Ranjana Mathur, Jacob Y C Cheng, Doric Wong, Tien Yin WongAbstract:Purpose We aimed to evaluate the long-term natural history of Polypoidal Choroidal Vasculopathy (PCV) in untreated patients.
-
understanding indocyanine green angiography in Polypoidal Choroidal Vasculopathy the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy
Retina-the Journal of Retinal and Vitreous Diseases, 2014Co-Authors: Chui Ming Gemmy Cheung, Timothy Y Y Lai, Shihjen Chen, Victor Chong, Won Ki Lee, Hla Myint Htoon, Yuichiro Ogura, Tien Yin WongAbstract:Purpose:To evaluate the angiographic features in using fundus camera–based versus confocal scanning laser ophthalmoscope (cSLO)-based indocyanine green angiography in differentiating Polypoidal Choroidal Vasculopathy (PCV) from typical age-related macular degeneration.Methods:Sixty-five eyes of 44 p
Tien Yin Wong - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of a novel personalised aflibercept monotherapy regimen based on Polypoidal lesion closure in participants with Polypoidal Choroidal Vasculopathy
British Journal of Ophthalmology, 2021Co-Authors: Kelvin Yi Chong Teo, Tien Yin Wong, Ranjana Mathur, Anna C S Tan, Ian Yeo, Choi Mun Chan, Janice Marie Jordanyu, Usha Chakravarthy, Chui Ming Gemmy CheungAbstract:PURPOSE To compare the efficacy of aflibercept using a personalised versus fixed regimen in treatment-naive participants with Polypoidal Choroidal Vasculopathy (PCV). DESIGN A 52-week, randomised, open-label, non-inferiority, single-centre study that included participants with symptomatic PCV. Participants were randomised (3:1 ratio) to receive either personalised (n=40) or fixed 8-weekly treatment regimen (n=13). The personalised regimen allowed for either early treat and extend (TE difference 0.16, 95% CI -2.8 to 2.4, p=0.79). There was greater reduction in mean CSFT (SD) in the personalised versus fixed group (-248.8 (169.9) vs -164.8 (148.9) µm, p=0.03). Closure of PL occurred in 21 (55.2%) and 5 (41.6%) of study eyes in personalised and fixed groups, respectively at week 52 (p=0.41). CONCLUSIONS Personalised regimen achieved non-inferior BCVA gain and numerically higher PL closure compared with fixed regimen. TRIAL REGISTRATION NUMBER NCT03117634.
-
efficacy and safety of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy two year results of the aflibercept in Polypoidal Choroidal Vasculopathy study
American Journal of Ophthalmology, 2019Co-Authors: Tien Yin Wong, Chui Ming Gemmy Cheung, Shihjen Chen, Won Ki Lee, Yuichiro Ogura, Tomohiro Iida, Sergio Leal, Paul Mitchell, Zhongqi Zhang, Tatsuro IshibashiAbstract:Purpose We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with Polypoidal Choroidal Vasculopathy (PCV). Design This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers. Methods In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73–24 Early Treatment Diabetic Retinopathy Study letters (20/40–20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated. Results Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained (+10.7 vs +9.1, P = .48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed. Conclusion IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit.
-
Choroidal thickness changes in age related macular degeneration and Polypoidal Choroidal Vasculopathy a 12 month prospective study
American Journal of Ophthalmology, 2016Co-Authors: Daniel Shu Wei Ting, Tien Yin Wong, Ranjana Mathur, Choi Mun Chan, Wei Yan Ng, Si Rui Ng, Chui Ming Gemmy CheungAbstract:Purpose To describe 12-month changes in Choroidal thickness after anti–vascular endothelial growth factor (anti-VEGF) therapy for typical age-related macular degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV). Design Prospective, consecutive, noninterventional, longitudinal case series. Methods This study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month period. We used spectral-domain optical coherence tomography with enhanced depth imaging mode to measure Choroidal thickness. Results Of the 163 patients, 77 had typical AMD and 86 had PCV. Patients with PCV were younger (67.6 vs 72.5 years, P P = .02) than patients with typical AMD. Baseline subfoveal Choroidal thickness was not significantly different between PCV and typical AMD eyes, and was thicker in the study eye compared to fellow eye in the typical AMD group (223.1 vs 208.8 μm, P P P P = .04) and smoking (OR: 7.6, P = .03) at baseline, but not with age, refractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy, or baseline Choroidal thickness. Conclusions A significant reduction in subfoveal Choroidal thickness was noted after anti-VEGF therapy in typical AMD and PCV. Choroidal thickness changes were similar despite differences in number of anti-VEGF treatment.
-
the natural history of Polypoidal Choroidal Vasculopathy a multi center series of untreated asian patients
Graefes Archive for Clinical and Experimental Ophthalmology, 2015Co-Authors: Chui Ming Gemmy Cheung, Elizabeth Yang, Ranjana Mathur, Jacob Y C Cheng, Doric Wong, Tien Yin WongAbstract:Purpose We aimed to evaluate the long-term natural history of Polypoidal Choroidal Vasculopathy (PCV) in untreated patients.
-
understanding indocyanine green angiography in Polypoidal Choroidal Vasculopathy the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy
Retina-the Journal of Retinal and Vitreous Diseases, 2014Co-Authors: Chui Ming Gemmy Cheung, Timothy Y Y Lai, Shihjen Chen, Victor Chong, Won Ki Lee, Hla Myint Htoon, Yuichiro Ogura, Tien Yin WongAbstract:Purpose:To evaluate the angiographic features in using fundus camera–based versus confocal scanning laser ophthalmoscope (cSLO)-based indocyanine green angiography in differentiating Polypoidal Choroidal Vasculopathy (PCV) from typical age-related macular degeneration.Methods:Sixty-five eyes of 44 p
Nagahisa Yoshimura - One of the best experts on this subject based on the ideXlab platform.
-
Microperimetry and multimodal imaging in Polypoidal Choroidal Vasculopathy
Scientific reports, 2018Co-Authors: Jennifer H. Acton, Ken Ogino, Yumiko Akagi, John Millington Wild, Nagahisa YoshimuraAbstract:Polypoidal Choroidal Vasculopathy (PCV) is a degenerative macular disease. The study determined the topographical concordance in the areal extent of PCV, defined by indocyanine green angiography (ICGA), and the corresponding outcomes from spectral-domain optical coherence tomography (SD-OCT) and microperimetry, in 25 individuals (25 eyes) who had undergone 3 months of anti-vascular endothelial growth factor treatment. The differential light sensitivity within 10° eccentricity was evaluated by Pattern Deviation probability analysis. The concordances and proportional areal extents of the abnormality for ICGA, SD-OCT and microperimetry were compared. The concordance in the areal extent between all three modalities was 59%. The median concordance between ICGA and microperimetry was 60%; between ICGA and SD-OCT, 70%; and between SD-OCT and microperimetry, 72%. SD-OCT and microperimetry each identified a greater areal extent (>20%) compared to ICGA in 13 and 19 eyes, respectively. A greater areal extent (>20%) was present in 9 eyes for microperimetry compared to SD-OCT and in 5 eyes for SD-OCT compared to microperimetry. SD-OCT and microperimetry each identified a greater area of abnormality than ICGA which supports the clinical utility of SD-OCT. Strong concordance was present between SD-OCT and microperimetry; however, microperimetry identified additional areas of functional abnormality.
-
effects of aflibercept for ranibizumab resistant neovascular age related macular degeneration and Polypoidal Choroidal Vasculopathy
Graefes Archive for Clinical and Experimental Ophthalmology, 2015Co-Authors: Yu Kawashima, Akitaka Tsujikawa, Akio Oishi, Kenji Yamashiro, Masahiro Miyake, Naoko Uedaarakawa, Munemitsu Yoshikawa, Ayako Takahashi, Nagahisa YoshimuraAbstract:Purpose To evaluate visual and anatomic outcomes in response to the conversion of treatment in patients with neovascular age-related macular degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV) refractory to previous treatment. We also investigated the effect of genetic factors.
-
indocyanine green angiography guided photodynamic therapy for Polypoidal Choroidal Vasculopathy
American Journal of Ophthalmology, 2007Co-Authors: Atsushi Otani, Akitaka Tsujikawa, Hiroshi Tamura, Manabu Sasahara, Yuko Yodoi, Hiroko Aikawa, Nagahisa YoshimuraAbstract:Purpose To report the 12-month follow-up results of subfoveal Polypoidal Choroidal Vasculopathy (PCV) patients treated with indocyanine green angiography (ICGA)-guided photodynamic therapy (PDT). Design Interventional, noncomparative cases series. Methods A retrospective analysis of the clinical and angiographic data related to 47 PCV eyes that were followed up for 12 months was carried out. The greatest linear dimension (GLD) for PDT was determined based on the ICGA findings. Optical coherence tomography (OCT) also was used to evaluate the therapeutic effects. Results The mean logarithm of the minimum angle of resolution visual acuity (VA; 0.58 ± 0.37) significantly improved to 0.53 ± 0.38 at three months (P = .04) and to 0.46 ± 0.40 at 12 months (P = .02). The average ICGA GLD (2682.3 ± 1026.9 mm) was significantly (P = .0001) smaller than the presumed fluorescein angiography (FA) GLD (4043.6 ± 1914.8 mm). In more than 80% of cases, complete resolution of retinal exudative changes was observed. Although Polypoidal vascular lesions disappeared in 82.2% of eyes, the branched vascular networks showed little change. The initial VA and GLD had little correlation with the VA outcome. Conclusions ICGA-guided PDT reduces the size of laser exposure and is an effective treatment for PCV. Because PCV may appear as occult Choroidal neovascularization (CNV) on FA, PCV should be diagnosed using ICGA before treatment because PCV may respond differently than CNV to appropriate treatment.
Tomohiro Iida - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy two year results of the aflibercept in Polypoidal Choroidal Vasculopathy study
American Journal of Ophthalmology, 2019Co-Authors: Tien Yin Wong, Chui Ming Gemmy Cheung, Shihjen Chen, Won Ki Lee, Yuichiro Ogura, Tomohiro Iida, Sergio Leal, Paul Mitchell, Zhongqi Zhang, Tatsuro IshibashiAbstract:Purpose We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with Polypoidal Choroidal Vasculopathy (PCV). Design This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers. Methods In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73–24 Early Treatment Diabetic Retinopathy Study letters (20/40–20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated. Results Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained (+10.7 vs +9.1, P = .48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed. Conclusion IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit.
-
one year results of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy
Ophthalmology, 2015Co-Authors: Akiko Yamamoto, Masaaki Saito, Mariko Kano, Hideki Koizumi, Ichiro Maruko, Tetsuju Sekiryu, Annabelle A Okada, Tomohiro IidaAbstract:Purpose To investigate 1-year outcomes of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy (PCV). Design Retrospective, multicenter, consecutive case series. Participants A total of 90 eyes of 87 patients with treatment-naive PCV followed at 3 tertiary centers. Methods Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening. Main Outcome Measures Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year. Results The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months ( P P Conclusions Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naive eyes with PCV.
-
intravitreal ranibizumab for Polypoidal Choroidal Vasculopathy with recurrent or residual exudation
Retina-the Journal of Retinal and Vitreous Diseases, 2011Co-Authors: Masaaki Saito, Tomohiro Iida, Mariko KanoAbstract:PURPOSE To clarify the efficiency of ranibizumab for Polypoidal Choroidal Vasculopathy in patients with regressed Polypoidal lesions after previous photodynamic therapy (PDT) applications but recurrent or residual exudation from branching vascular network vessels. METHODS We retrospectively reviewed 59 eyes of 59 Japanese patients (47 men and 12 women) with Polypoidal Choroidal Vasculopathy. Treatments were chosen according to the period. Thirty-four patients were treated with PDT (PDT group) and 25 patients were treated with intravitreal injections of ranibizumab (ranibizumab group). RESULTS In the ranibizumab group, the mean best-corrected visual acuity levels at baseline and 6 months were 0.27 and 0.41, respectively, showing a significant (P 1 disk diameter) developed in 5 eyes in the PDT group. CONCLUSION Intravitreal ranibizumab is an effective treatment for maintaining or improving visual acuity and the anatomical changes in patients with Polypoidal Choroidal Vasculopathy with recurrent or residual exudation from branching vascular network vessels.
-
subfoveal retinal and Choroidal thickness after verteporfin photodynamic therapy for Polypoidal Choroidal Vasculopathy
American Journal of Ophthalmology, 2011Co-Authors: Ichiro Maruko, Tomohiro Iida, Masaaki Saito, Yukinori Sugano, Tetsuju SekiryuAbstract:Purpose To evaluate the morphologic retinal and Choroidal changes after verteporfin photodynamic therapy (PDT) with and without ranibizumab for Polypoidal Choroidal Vasculopathy using spectral-domain optical coherence tomography. Design Retrospective, comparative series. Methods The enhanced depth imaging optical coherence tomography technique was used in this retrospective, comparative series to measure the subfoveal retinal and Choroidal thicknesses before and after treatment. Results Twenty-seven eyes with Polypoidal Choroidal Vasculopathy were examined retrospectively. Sixteen eyes were treated with PDT monotherapy (PDT group). Eleven eyes were treated with PDT after intravitreal ranibizumab injection (ranibizumab plus PDT group). The Polypoidal lesions regressed in all cases at 3 months. The mean retinal thickness, including the retinal detachment, increased from 401 ± 157 μm before treatment to 506 ± 182 μm 2 days after PDT ( P P = .03) and 265 ± 127 μm by 6 months after treatment ( P P P = .24) and 229 ± 104 μm by 6 months ( P Conclusions PDT was associated with decreased retinal and Choroidal thicknesses. Combination therapy reduced the transient exudation after PDT in some cases, and monthly intravitreal ranibizumab injections maintained retinal thinning and seemed to improve vision better than PDT monotherapy.
-
subfoveal retinal and Choroidal thickness after verteporfin photodynamic therapy for Polypoidal Choroidal Vasculopathy
American Journal of Ophthalmology, 2011Co-Authors: Ichiro Maruko, Tomohiro Iida, Masaaki Saito, Yukinori Sugano, Tetsuju SekiryuAbstract:Purpose To evaluate the morphologic retinal and Choroidal changes after verteporfin photodynamic therapy (PDT) with and without ranibizumab for Polypoidal Choroidal Vasculopathy using spectral-domain optical coherence tomography. Design Retrospective, comparative series. Methods The enhanced depth imaging optical coherence tomography technique was used in this retrospective, comparative series to measure the subfoveal retinal and Choroidal thicknesses before and after treatment. Results Twenty-seven eyes with Polypoidal Choroidal Vasculopathy were examined retrospectively. Sixteen eyes were treated with PDT monotherapy (PDT group). Eleven eyes were treated with PDT after intravitreal ranibizumab injection (ranibizumab plus PDT group). The Polypoidal lesions regressed in all cases at 3 months. The mean retinal thickness, including the retinal detachment, increased from 401 ± 157 μm before treatment to 506 ± 182 μm 2 days after PDT ( P P = .03) and 265 ± 127 μm by 6 months after treatment ( P P P = .24) and 229 ± 104 μm by 6 months ( P Conclusions PDT was associated with decreased retinal and Choroidal thicknesses. Combination therapy reduced the transient exudation after PDT in some cases, and monthly intravitreal ranibizumab injections maintained retinal thinning and seemed to improve vision better than PDT monotherapy.
Masaaki Saito - One of the best experts on this subject based on the ideXlab platform.
-
one year results of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy
Ophthalmology, 2015Co-Authors: Akiko Yamamoto, Masaaki Saito, Mariko Kano, Hideki Koizumi, Ichiro Maruko, Tetsuju Sekiryu, Annabelle A Okada, Tomohiro IidaAbstract:Purpose To investigate 1-year outcomes of intravitreal aflibercept for Polypoidal Choroidal Vasculopathy (PCV). Design Retrospective, multicenter, consecutive case series. Participants A total of 90 eyes of 87 patients with treatment-naive PCV followed at 3 tertiary centers. Methods Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening. Main Outcome Measures Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year. Results The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months ( P P Conclusions Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naive eyes with PCV.
-
initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of Polypoidal Choroidal Vasculopathy the fujisan study
Retina-the Journal of Retinal and Vitreous Diseases, 2015Co-Authors: Fumi Gomi, Ryusaburo Mori, Masaaki Saito, Mariko Kano, Yuji Oshima, Ayana Yamashita, Eiji Iwata, Ruka MarukoAbstract:Purpose:To compare the 1-year results of initial or deferred photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) for eyes with Polypoidal Choroidal Vasculopathy.Methods:Prospectively, 72 men with treatment-naive Polypoidal Choroidal Vasculopathy were randomized to initial or late
-
intravitreal ranibizumab for Polypoidal Choroidal Vasculopathy with recurrent or residual exudation
Retina-the Journal of Retinal and Vitreous Diseases, 2011Co-Authors: Masaaki Saito, Tomohiro Iida, Mariko KanoAbstract:PURPOSE To clarify the efficiency of ranibizumab for Polypoidal Choroidal Vasculopathy in patients with regressed Polypoidal lesions after previous photodynamic therapy (PDT) applications but recurrent or residual exudation from branching vascular network vessels. METHODS We retrospectively reviewed 59 eyes of 59 Japanese patients (47 men and 12 women) with Polypoidal Choroidal Vasculopathy. Treatments were chosen according to the period. Thirty-four patients were treated with PDT (PDT group) and 25 patients were treated with intravitreal injections of ranibizumab (ranibizumab group). RESULTS In the ranibizumab group, the mean best-corrected visual acuity levels at baseline and 6 months were 0.27 and 0.41, respectively, showing a significant (P 1 disk diameter) developed in 5 eyes in the PDT group. CONCLUSION Intravitreal ranibizumab is an effective treatment for maintaining or improving visual acuity and the anatomical changes in patients with Polypoidal Choroidal Vasculopathy with recurrent or residual exudation from branching vascular network vessels.
-
subfoveal retinal and Choroidal thickness after verteporfin photodynamic therapy for Polypoidal Choroidal Vasculopathy
American Journal of Ophthalmology, 2011Co-Authors: Ichiro Maruko, Tomohiro Iida, Masaaki Saito, Yukinori Sugano, Tetsuju SekiryuAbstract:Purpose To evaluate the morphologic retinal and Choroidal changes after verteporfin photodynamic therapy (PDT) with and without ranibizumab for Polypoidal Choroidal Vasculopathy using spectral-domain optical coherence tomography. Design Retrospective, comparative series. Methods The enhanced depth imaging optical coherence tomography technique was used in this retrospective, comparative series to measure the subfoveal retinal and Choroidal thicknesses before and after treatment. Results Twenty-seven eyes with Polypoidal Choroidal Vasculopathy were examined retrospectively. Sixteen eyes were treated with PDT monotherapy (PDT group). Eleven eyes were treated with PDT after intravitreal ranibizumab injection (ranibizumab plus PDT group). The Polypoidal lesions regressed in all cases at 3 months. The mean retinal thickness, including the retinal detachment, increased from 401 ± 157 μm before treatment to 506 ± 182 μm 2 days after PDT ( P P = .03) and 265 ± 127 μm by 6 months after treatment ( P P P = .24) and 229 ± 104 μm by 6 months ( P Conclusions PDT was associated with decreased retinal and Choroidal thicknesses. Combination therapy reduced the transient exudation after PDT in some cases, and monthly intravitreal ranibizumab injections maintained retinal thinning and seemed to improve vision better than PDT monotherapy.
-
subfoveal retinal and Choroidal thickness after verteporfin photodynamic therapy for Polypoidal Choroidal Vasculopathy
American Journal of Ophthalmology, 2011Co-Authors: Ichiro Maruko, Tomohiro Iida, Masaaki Saito, Yukinori Sugano, Tetsuju SekiryuAbstract:Purpose To evaluate the morphologic retinal and Choroidal changes after verteporfin photodynamic therapy (PDT) with and without ranibizumab for Polypoidal Choroidal Vasculopathy using spectral-domain optical coherence tomography. Design Retrospective, comparative series. Methods The enhanced depth imaging optical coherence tomography technique was used in this retrospective, comparative series to measure the subfoveal retinal and Choroidal thicknesses before and after treatment. Results Twenty-seven eyes with Polypoidal Choroidal Vasculopathy were examined retrospectively. Sixteen eyes were treated with PDT monotherapy (PDT group). Eleven eyes were treated with PDT after intravitreal ranibizumab injection (ranibizumab plus PDT group). The Polypoidal lesions regressed in all cases at 3 months. The mean retinal thickness, including the retinal detachment, increased from 401 ± 157 μm before treatment to 506 ± 182 μm 2 days after PDT ( P P = .03) and 265 ± 127 μm by 6 months after treatment ( P P P = .24) and 229 ± 104 μm by 6 months ( P Conclusions PDT was associated with decreased retinal and Choroidal thicknesses. Combination therapy reduced the transient exudation after PDT in some cases, and monthly intravitreal ranibizumab injections maintained retinal thinning and seemed to improve vision better than PDT monotherapy.